xpo1

XPO1-IN-1 is an orally active XPO1 inhibitor capable of acting on MM.1S cells (IC50: 24 nM). XPO1-IN-1 effectively induces cell cycle arrest and apoptosis. XPO1-IN-1 exhibits good metabolic stability and pharmacokinetic properties. XPO1-IN-1 can be used to study multiple myeloma.

Verdinexor (KPT-335) (KPT-335), a specific XPO1/CRM1 inhibitor, are orally bioavailable.

Eltanexor (ONO-7706) is an orally active exportin-1 (XPO1) inhibitor. It has effective anti-leukemic activity. Eltanexor inhibits XPO1-dependent nuclear export (EC50=60.9 nM) by directly targeting XPO1. Eltanexor causes caspase-dependent apoptosis in a panel of leukemic cell lines.

KPT-251 is a selective nuclear export inhibitor.

Leptomycin B (LMB) is a potent inhibitor of the nuclear export of proteins and is a potent antifungal antibiotic blocking the eukaryotic cell cycle. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue.